The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Overall survival in patients with cHL who progress after autoSCT in the era of novel agents
Sanjal Desai, MBBS, University of Minnesota, Minneapolis, MN, shares the findings of a retrospective study investigating whether treatment with novel agents has improved overall survival (OS) in patients with classic Hodgkin lymphoma (cHL) who progress following autologous stem cell transplantation (autoSCT). The outcomes of 300 patients with cHL who progressed after autoSCT were analyzed, where patients either received brentuximab vedotin (BV) or the checkpoint inhibitor nivolumab. Dr Desai highlights factors which influenced OS in these patients, and further comments on the outcomes of patients who were bridged to receive allogeneic SCT. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
